ATH 0.00% 1.7¢ alterity therapeutics limited

+ + data and comment + +

  1. 22,691 Posts.
    7.15 mill shares issued at 70 cents and about $5 mil was raised taking cash holdings to $7 mill.:


    "On 5 August 2003 Prana announced that its highly successful medicinal chemistry program had created a library of approx. 300 compounds specifically engineered to address age-related neurodegenerative diseases such as Alzheimers Disease.

    From these compounds the Company’s technical review committee selected an NCE (New Chemical Entity) which has been code-named

    PBT-2 to advance to human clinical trials. This follows the successful completion of Prana’s recent proof of concept trial utilising clioquinol (PBT-1), an existing off-label drug previously prescribed for a non-related application.

    PBT-2 is a new proprietary compound developed by Prana scientists to specifically target Alzheimers Disease.

    It is owned exclusively by Prana and has significantly outperformed PBT-1 in the laboratory and animal trials undertaken to date.

    Given the success of the previous human trials of PBT-1 the Board of Prana and its scientists approach the clinical phase of PBT-2 with heightened confidence".
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Mkt cap ! $15.17M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 27237 1.7¢

Sellers (Offers)

Price($) Vol. No.
1.8¢ 19478 1
View Market Depth
Last trade - 10.05am 18/02/2020 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.